前列地尔联合缬沙坦治疗糖尿病肾病的疗效观察

目的观察前列地尔联合缬沙坦治疗糖尿病肾病的临床效果。方法 74例糖尿病肾病患者随机分为两组,对照组(n=37例)在常规对症支持疗法的治疗基础上采取缬沙坦药物治疗,观察组(n=37例)在对照组治疗基础上采取前列地尔治疗,两组疗程均为3个月。观察治疗前后两组24h尿蛋白排泄量(24 h Upr)、血尿素氮(BUN)和肌酐(Cr)等指标变化情况。结果观察组治疗总有效率为81.1%,对照组治疗总有效率为64.9%,两组治疗总有效率比较有显著差异性(P<0.05);两组患者治疗前24 h Upr、Scr和BUN等肾功能指标无显著差异性(P>0.05),两组治疗后上述指标均明显下降,但观察组24 h Upr下降更为显著(P<0.05)。结论前列地尔联合缬沙坦治疗糖尿病肾病疗效显著,值得临床推广应用。

Clinical observation on the efficacy of alprostadil combined with valsartan in treatment of diabetic nephropathy

Objective To observe the clinical efficacy of alprostadil combined with valsartan in treatment of patients with diabetic nephropathy. Methods A total of 74 patients with diabetic nephropathy were randomly divided into two groups. Patients in control group were treated with valsartan on the basis of basic treatment, and patients in observation group were treated with alprostadil and valsartan on the basis of basic treatment. The course of treatment in two groups was 3 months. The changes in 24 h urinary protein excretion （24 h Upr）, blood levels of urea nitrogen （BUN） and creatinine （Cr） in two groups were observed before and after treatment. Results The total rate of efficacy in patients of observation group （81.1% ） was significantly higher than that of patients in control group （64.9%） （ P 〈 0.05 ）. The indicators of 24 h Upr, Scr and BUN in patients of two groups were all decreased, but the indicator of 24 h Upr in patients of observation group declined more significantly than that of control group （ P 〈 0.05 ）. Conclusion The treatment of alprostadil combined with valsartan for diabetic nephropathy has good efficacy. It is worthy to be recommended for clinical application.